Assessing sequence-dependent off-target risks is a critical step during siRNA development to ensure the safety and specificity of therapeutic candidate molecules. This process starts during in-silico siRNA design, where potential RNAi-mediated off-targets are first predicted. This webinar provides an overview of how this has traditionally been approached and explores potential blind spots of such methods, as revealed by untargeted RNAseq-based experiments. It also highlights the challenges associated with expanding the off-target search space, namely the explosion in false positive rate, and explores the potential of solutions like machine learning for counteracting this.

https://www.oligotherapeutics.org/in-...